Hereditary Hemorrhagic Telangiectasia
1
Pipeline Programs
6
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Oregon TherapeuticsFrance - Paris
1 programComprehensive HHT Outcomes Registry of the United States (CHORUS)N/A
Colorado TherapeuticsCO - Louisville
1 programComprehensive HHT Outcomes Registry of the United States (CHORUS)N/A
Angeles TherapeuticsCA - Los Angeles
1 programComprehensive HHT Outcomes Registry of the United States (CHORUS)N/A1 trial
Active Trials
HELP TherapeuticsChina - Nanjing
1 programNationwide Awareness Campaign and Call for Dental Screening for HHT in GermanyN/A1 trial
Active Trials
Baxter InternationalDEERFIELD, IL
1 programTranexamic acid first, than placeboPHASE_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Baxter InternationalTranexamic acid first, than placebo
Angeles TherapeuticsComprehensive HHT Outcomes Registry of the United States (CHORUS)
HELP TherapeuticsNationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
Clinical Trials (3)
Total enrollment: 10,023 patients across 3 trials
Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Start: Mar 2002Est. completion: Oct 200223 patients
Phase 3Completed
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Start: Nov 2023Est. completion: Nov 203310,000 patients
N/ARecruiting
NCT03549949HELP TherapeuticsNationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
Start: Jun 2018Est. completion: Jul 2022
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 10,023 patients
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.